Key result
Ambulatory levosimendan linked to ~21% higher stroke volume at 48 hours in advanced HF.
Why the study?
Although ambulatory infusions of levosimendan improve quality of life and reduce hospitalizations in advanced heart failure, their effects on echocardiographic markers of perfusion, congestion, and cardiovascular efficiency needed evaluation.
Does ambulatory infusion of levosimendan improve echocardiographic markers of perfusion and congestion in outpatients with advanced heart failure?
Does ambulatory infusion of levosimendan improve echocardiographic markers of perfusion and congestion in outpatients with advanced heart failure?
Ambulatory infusion of levosimendan in advanced heart failure patients significantly improves echocardiographic hemodynamic markers of perfusion and congestion at 48 hours.
Answers are grounded in this paper and cite their sources.
May support short-term hemodynamic improvement in advanced HF outpatients; leaves open clinical outcomes and requires randomized confirmation.
Infusions of levosimendan delivered in ambulatory/outpatient settings have been shown to improve quality of life and reduce hospitalizations in patients with advanced heart failure (HF). The aim of this pilot study was to evaluate the effects of ambulatory infusion of levosimendan on echocardiographic markers of perfusion, congestion, and cardiovascular efficiency. Thirty patients with diagnosed advanced HF underwent ambulatorial infusion of levosimendan at a total dose of 6.25 mg as a part of a repetitive biweekly treatment strategy with the inotrope. Standardized transthoracic echocardiography and Doppler examinations, were performed 1 hour before and 48 hours after completion of ambulatory infusion. At 48 hours after ambulatory infusion of levosimendan, a significant increase in the stroke volume (37.47 ± 12.38 mL/beat vs. 45.47 ± 14.48 mL/beat; P < 0.05) and cardiac output (2.64 ± 0.66 L/min vs. 3.26 ± 0.57 L/min; P < 0.05) occurred. Significant postreductions versus prereductions were also recorded in left atrial pressure (27.37 ± 6.62 mm Hg vs. 22.82 ± 4.17 mm Hg; P < 0.01), mean pulmonary artery pressure (27.69 ± 4.64 mm Hg vs. 23.24 ± 5.32; P < 0.01), and inferior vena cava diameter (23.81 ± 7.63 mm vs. 18.53 ± 4.82 mm; P < 0.01). Significant improvements were noted in the resting cardiac power output (0.46 ± 0.15 watt vs. 0.53 ± 0.22 watt; P < 0.01) and the resting cardiac power index (0.24 ± 0.08 watt/m2 vs. 0.28 ± 0.11 watt/m2; P < 0.01). In outpatients with advanced HF, infusion of levosimendan was associated with hemodynamic responses that may contribute to the clinical benefit previously reported in such patients.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied Advanced heart failure (n=30). Levosimendan vs. Baseline (1 hour before infusion) was evaluated on Stroke volume (p=< 0.05). Ambulatory infusion of levosimendan in outpatients with advanced heart failure increased stroke volume and cardiac output at 48 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: